Vaccination with adenovirus serotypes 35, 26, and 48 elicits higher levels of innate cytokine responses than adenovirus serotype 5 in rhesus monkeys

Journal of Virology

Volumn 86, Issue 18, 2012, Pages 9590-9598

  Teigler, Jeffrey E ^a,b   Iampietro, M Justin ^a,b   Barouch, Dan H ^a,b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 6; MEMBRANE COFACTOR PROTEIN; VIRUS VACCINE;

ADENOVIRUS; ADENOVIRUS 26; ADENOVIRUS 35; ADENOVIRUS 48; ADENOVIRUS 5; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL POPULATION; CONTROLLED STUDY; CYTOKINE RESPONSE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; MOLECULAR INTERACTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN INDUCTION; RHESUS MONKEY; SEROTYPE;

ADENOVIRUSES, HUMAN; ANIMALS; ANTIGENS, CD46; CHEMOKINES; COXSACKIE AND ADENOVIRUS RECEPTOR-LIKE MEMBRANE PROTEIN; CYTOKINES; GENETIC VECTORS; HUMANS; IMMUNITY, INNATE; MACACA MULATTA; RECEPTORS, VIRUS; SEROTYPING; SPECIES SPECIFICITY; VACCINATION;

ADENOVIRIDAE; COXSACKIEVIRUS; MACACA MULATTA; MIRIDAE;

EID: 84866152532     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00740-12     Document Type: Article

References (53)

1. Abbink P, et al. 2007. Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J. Virol. 81:4654-4663.
2. Adams WC, et al. 2011. Adenovirus type-35 vectors block human CD4+ T-cell activation via CD46 ligation. Proc. Natl. Acad. Sci. U. S. A. 108:7499-7504.
3. Appledorn DM, et al. 2008. Wild-type adenoviruses from groups A-F evoke unique innate immune responses, of which HAd3 and SAd23 are partially complement dependent. Gene Ther. 15:885-901.
4. Appledorn DM, et al. 2008. Complex interactions with several arms of the complement system dictate innate and humoral immunity to adenoviral vectors. Gene Ther. 15:1606-1617.
5. Barilla-LaBarca ML, Liszewski MK, Lambris JD, Hourcade D, Atkinson JP. 2002. Role of membrane cofactor protein (CD46) in regulation of C4b and C3b deposited on cells. J. Immunol. 168:6298-6304.
6. Barouch DH, et al. 2009. Protective efficacy of a single immunization of a chimeric adenovirus vector-based vaccine against simian immunodeficiency virus challenge in rhesus monkeys. J. Virol. 83:9584-9590.
7. Barouch DH, et al. 2012. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature 482:89-93.
8. Bennett S, Breit SN. 1994. Variables in the isolation and culture of human monocytes that are of particular relevance to studies of HIV. J. Leukoc.Biol. 56:236-240.
9. Bergelson JM. 1997. Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5. Science 275:1320-1323.
10. Berk Arnold J. 2007. Adenoviridae: the viruses and their replication, p 2355-2394. In Knipe DM, Howley PM (ed), Fields virology, 5th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
11. DiPaolo N, et al. 2006. Evaluation of adenovirus vectors containing serotype 35 fibers for vaccination. Mol. Ther. 13:756-765.
12. Di Paolo NC, et al. 2009. Virus binding to a plasma membrane receptor triggers interleukin-1a-mediated proinflammatory macrophage response in vivo. Immunity 31:110-121.
13. Gaggar A, Shayakhmetov DM, Lieber A. 2003. CD46 is a cellular receptor for group B adenoviruses. Nat. Med. 9:1408-1412.
14. Gastaldelli M, et al. 2008. Infectious adenovirus type 2 transport through early but not late endosomes. Traffic 9:2265-2278.
15. Greig JA, et al. 2009. Influence of coagulation factor X on in vitro and in vivo gene delivery by adenovirus (Ad) 5, Ad35, and chimeric Ad5/Ad35 vectors. Mol. Ther. 17:1683-1691.
16. Havenga MJ, et al. 2002. Exploiting the natural diversity in adenovirus tropism for therapy and prevention of disease exploiting the natural diversity in adenovirus tropism for therapy and prevention of disease. J. Virol. 76:4612-4620.
17. Hsu K-H, Lonberg-Holm K, Alstein B, Crowell RL. 1988. A monoclonal antibody specific for the cellular receptor for the group B coxsackieviruses. J. Virol. 62:1647-1652.
18. Iacobelli-Martinez M, Nemerow GR. 2007. Preferential activation of Toll-like receptor nine by CD46-utilizing adenoviruses. J. Virol. 81:1305-1312.
19. Iacobelli-Martinez, M, Nepomuceno RR, Connolly J, Nemerow GR. 2005. CD46-utilizing adenoviruses inhibit C/EBPβ-dependent expression of proinflammatory cytokines. J. Virol. 79:11259-11268.
20. Johnson MJ, et al. 2012. Type I IFN induced by adenovirus serotypes 28 and 35 has multiple effects on T cell immunogenicity. J. Immunol. 188:6109-6118.
21. Joubert P-E, et al. 2009. Autophagy induction by the pathogen receptor CD46. Cell Host Microbe 6:354-366.
22. Kälin S, et al. 2010. Macropinocytotic uptake and infection of human epithelial cells with species B2 adenovirus type 35. J. Virol. 84:5336-5350.
23. Kaufman DR, et al. 2008. Trafficking of antigen-specific CD8+ T lymphocytes to mucosal surfaces following intramuscular vaccination. J. Immunol. 181:4188-4198.
24. Kemper C, et al. 2001. Membrane cofactor protein (MCP; CD46) expression in transgenic mice. Clin. Exp. Immunol. 124:180-189.
25. Liszewski MK, Post TW, Atkinson JP. 1991. Membrane cofactor protein (MCP or CD46): newest member of the regulators of complement activation gene cluster. Annu. Rev. Immunol. 9:431-455.
26. Liu EB, et al. 2011. Genetic analysis of a novel human adenovirus with a serologically unique hexon and a recombinant fiber gene. PLoS One 6:e24491. doi:10.1371/journal.pone.0024491.
27. Liu J, et al. 2008. Magnitude and phenotype of cellular immune responses elicited by recombinant adenovirus vectors and heterologous prime-boost regimens in rhesus monkeys. J. Virol. 82:4844-4852.
28. Liu J, et al. 2009. Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature 457:87-91.
29. Loré K, et al. 2011. Myeloid and plasmacytoid dendritic cells are susceptible to recombinant adenovirus vectors and stimulate polyfunctional memory T cell responses. J. Immunol. 179:1721-1729.
30. Matsushima Y, et al. 2012. Novel human adenovirus strain, Bangaledesh. Emerg. Infect. Dis. 18:846-848.
31. Meier O, et al. 2002. Adenovirus triggers macropinocytosis and endosomal leakage together with its clathrin-mediated uptake. J. Cell Biol. 158: 1119-1131.
32. Miyazawa N, Crystal RG, Leopold PL. 2001. Adenovirus serotype 7 retention in a late endosomal compartment prior to cytosol escape is modulated by fiber protein. J. Virol. 75:1387-1400.
33. Mizuguchi H, Hayakawa T. 2002. Adenovirus vectors containing chimeric type 5 and type 35 fiber proteins exhibit altered and expanded tropism and increase the size limit of foreign genes. Gene 285:69-77.
34. Nanda A, et al. 2005. Immunogenicity of recombinant fiber-chimeric adenovirus serotype 35 vector-based vaccines in mice and rhesus monkeys. J. Virol. 79:14161-14168.
35. Nociari M, Ocheretina O, Schoggins JW, Falck-Pedersen E. 2007. Sensing infection by adenovirus: Toll-like receptor-independent viral DNA recognition signals activation of the interferon regulatory factor 3 master regulator. J. Virol. 81:4145-4157.
36. Ophorst OJ, et al. 2004. An adenoviral type 5 vector carrying a type 35 fiber as a vaccine vehicle: DC targeting, cross neutralization, and immunogenicity. Vaccine 22:3035-3044.
37. Post BTW, et al. 1991. Membrane cofactor protein of the complement system: alternative splicing of serine/threonine/proline-rich exons and cytoplasmic tails produces multiple isoforms that correlate with protein phenotype. J. Exp. Med. 174:93-102.
38. Purcell DFJ, et al. 1991. Alternatively spliced RNAs encode several isoforms of CD46 (MCP), a regulator of complement activation. Immunogenetics 33:335-344.
39. Roberts DM, et al. 2006. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature 441:239-243.
40. Roelvink PW. 1999. Identification of a conserved receptor-binding site on the fiber proteins of CAR-recognizing adenoviridae. Science 286:1568-1571.
41. Sakurai F, et al. 2006. The short consensus repeats 1 and 2, not the cytoplasmic domain, of human CD46 are crucial for infection of subgroup B adenovirus serotype 35. J. Control. Release 113:271-278.
42. Santra S, et al. 2009. Heterologous prime/boost immunizations of rhesus monkeys using chimpanzee adenovirus vectors. Vaccine 27:5837-5845.
43. Schneider-Schaulies J, Dunster LM, Schwartz-Albiez R, Krohne G, ter Meulen V. 1995. Physical association of moesin and CD46 as a receptor complex for measles virus. J. Virol. 69:2248-2256.
44. Schnell M, et al. 2001. Activation of innate immunity in nonhuman primates following intraportal administration of adenoviral vectors. Mol. Ther. 3:708-722.
45. Seya T, Hara T, Matsumoto M, Akedo H. 1990. Quantitative analysis of membrane cofactor protein (MCP) of complement. High expression of MCP on human leukemia cell lines, which is down-regulated during cell differentiation. J. Immunol. 145:238-245.
46. Sharma A, Bangari DS, Tandon M, Hogenesch H, Mittal SK. 2010. Evaluation of innate immunity and vector toxicity following inoculation of bovine, porcine or human adenoviral vectors in a mouse model. Virus Res. 153:134-142.
47. Varnavski AN, et al. 2002. Preexisting immunity to adenovirus in rhesus monkeys fails to prevent vector-induced toxicity. J. Virol. 76:5711-5719.
48. Waddington SN, et al. 2008. Adenovirus serotype 5 hexon mediates liver gene transfer. Cell 132:397-409.
49. Walsh MP, et al. 2010. Computational analysis identifies human adenovirus type 55 as a re-emergent acute respiratory disease pathogen. J. Clin. Microbiol. 48:991-993.
50. Wang H, et al. 2011. Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14. Nat. Med. 17:96-104.
51. Wiethoff CM, Wodrich H, Gerace L, Nemerow GR. 2005. Adenovirus protein VI mediates membrane disruption following capsid disassembly. J. Virol. 79:1992-2000.
52. Wu W, et al. 2010. Human lung innate immune cytokine response to adenovirus type 7. J. Gen. Virol. 91:1155-1163.
53. Zhang Y, et al. 2001. Acute cytokine response to systemic adenoviral vectors in mice is mediated by dendritic cells and macrophages. Mol. Ther. 3:697-707.